SCHEMBL496910

SCHEMBL496910

Cc1c(C)c(O)c2c(c1O)C(=O)c1ccccc1C2=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ELANE P08246 1/20 0.60
MEN1 O00255 8/20 0.59
KMT2A Q03164 8/20 0.59
MAPT P10636 7/20 0.59
MAOA P21397 6/20 0.59
KDM4E B2RXH2 4/20 0.59
DAPK1 P53355 3/20 0.59
HPGD P15428 3/20 0.59
ALDH1A1 P00352 3/20 0.59
MAPK1 P28482 3/20 0.59
RECQL P46063 3/20 0.59
TDP1 Q9NUW8 3/20 0.59
CYP3A4 P08684 2/20 0.59
ALOX15 P16050 2/20 0.59
ALOX12 P18054 2/20 0.59
CYP1B1 Q16678 2/20 0.59
HSD17B10 Q99714 2/20 0.59
TTR P02766 2/20 0.59
CYP1A1 P04798 1/20 0.59
HSPD1 P10809 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31238281 0.91 ELANE (0.56) ELANEMEN1KMT2AMAPTMAOA
SCHEMBL7100380 0.91 ELANE (0.56) ELANEMEN1KMT2AMAPTMAOA
SCHEMBL22719979 0.87 ELANE (0.56) ELANEMEN1KMT2AMAPTMAOA
SCHEMBL899150 0.85 MEN1 (0.68) ELANEMEN1KMT2AMAPTMAOA
SCHEMBL15315044 0.84 ELANE (0.53) ELANEMEN1KMT2AMAPTMAOA
SCHEMBL8581315 0.81 MEN1 (0.63) ELANEMEN1KMT2AMAPTMAOA
Rubiadin SCHEMBL1426928 0.81 BCL2 (0.71) ELANEMEN1KMT2AMAPTMAOA
Rubiadin SCHEMBL22616292 0.81 BCL2 (0.71) ELANEMEN1KMT2AMAPTMAOA
Rubiadin SCHEMBL30260037 0.81 BCL2 (0.71) ELANEMEN1KMT2AMAPTMAOA
Rubiadin SCHEMBL29665059 0.81 BCL2 (0.71) ELANEMEN1KMT2AMAPTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0705601-B1 Anthraquinones containing solutions for parenteral administration LOMAPHARM (DE) 2000-01-19 EP claimed
EP-0705601-A1 Anthraquinones containing solutions for parenteral administration LOMAPHARM Rudolf Lohmann GmbH KG Pharmazeutische Fabrik (DE) 1996-04-10 EP claimed
US-5385842-A Anthraquinones as inhibitors of sulfide production from sulfate-reducing bacteria E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-01-31 US claimed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 EP claimed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 EP claimed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 WO claimed
US-20220170904-A1 SYSTEMS AND METHODS FOR MONITORING BIOLOGICAL TISSUE DEGRADATION ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONA STATE UNIVERSITY (US) 2022-06-02 US disclosed
US-20220109157-A1 Conducting redox oligomers SJOEDIN MARTIN (SE) 2022-04-07 US disclosed
CN-113423755-A Conductive redox oligomers 马丁·舍丁 2021-09-21 CN disclosed
CN-109054427-B Dye, printing ink and electrowetting display device 深圳市国华光电科技有限公司 2021-04-20 CN disclosed
WO-2020162824-A1 CONDUCTING REDOX OLIGOMERS SJÖDIN MARTIN (SE) 2020-08-13 WO disclosed
US-8105477-B2 System and method for electrochemical detection of biological compounds HANDYLAB, INC. (US) 2012-01-31 US disclosed
US-20110039345-A1 SYSTEM AND METHOD FOR ELECTROCHEMICAL DETECTION OF BIOLOGICAL COMPOUNDS HANDYLAB, INC. (US) 2011-02-17 US disclosed
US-5385842-A Anthraquinones as inhibitors of sulfide production from sulfate-reducing bacteria E. I. DU PONT DE NEMOURS AND COMPANY (US) 1995-01-31 US disclosed
EP-0525073-B1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA DU PONT (US) 1994-05-25 EP disclosed
EP-0533744-A1 HETEROCYCLIC ANTHRACYCLIONE AND ANTHRACYCLINE ANALOGS BIOCHEM PHARMA INC. (CA) 1993-03-31 EP disclosed
EP-0525073-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA. DU PONT (US) 1993-02-03 EP disclosed
WO-1991019725-A2 HETEROCYCLIC ANTHRACYCLIONE AND ANTHRACYCLINE ANALOGS BIOCHEM PHARMA INC. (CA) 1991-12-26 WO disclosed
WO-1991015954-A1 ANTHRAQUINONES AS INHIBITORS OF SULFIDE PRODUCTION FROM SULFATE-REDUCING BACTERIA E.I. DU PONT DE NEMOURS AND COMPANY (US) 1991-10-31 WO disclosed
US-4457855-A HYDROPHOBIC LATEX PARTICLE THE CLOROX COMPANY (US) 1984-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220109157-A1 Conducting redox oligomers NOX4, CYBB, LPO ELANE 3112/4885MEN1 4105/4885KMT2A 2086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.